NCT05109091

Study of ATH434 in Participants with Multiple System Atrophy

A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Alterity Therapeutics · Industry
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

Conditions

• Multiple System Atrophy

Interventions

Type	Name	Description
DRUG	ATH434 dose level 1	ATH434 taken BID
DRUG	ATH434 dose level 2	ATH434 taken BID
DRUG	Placebo	Placebo taken BID

Timeline

• Start date: 2022-07-01
• Primary completion: 2024-11-28
• Completion: 2024-11-28
• First posted: 2021-11-05
• Last updated: 2024-12-13

Locations

23 sites across 6 countries: United States, Australia, France, Italy, New Zealand, United Kingdom

Regulatory

• FDA-regulated drug study